Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways
Open Access
- 1 February 2021
- Vol. 24 (2) , 102089
Abstract
No abstract availableKeywords
Funding Information
- Barts Charity
This publication has 40 references indexed in Scilit:
- Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activationJournal of Experimental Medicine, 2011
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignanciesBlood, 2011
- Antibodies against CD20 or B-Cell Receptor Induce Similar Transcription Patterns in Human Lymphoma Cell LinesPLOS ONE, 2011
- Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2Haematologica, 2010
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- Selective Use of ADAM10 and ADAM17 in Activation of Notch1 SignalingMolecular and Cellular Biology, 2009
- ADAMs 10 and 17 Represent Differentially Regulated Components of a General Shedding Machinery for Membrane Proteins Such as Transforming Growth Factor α, L-Selectin, and Tumor Necrosis Factor αMolecular Biology of the Cell, 2009
- Notch1 engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cellsProceedings of the National Academy of Sciences, 2007
- Phosphorylation of TNF-α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activationProceedings of the National Academy of Sciences, 2006
- Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic LeukemiaScience, 2004